Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Prophylactic efficacy of oral emtricitabine and tenofovir disoproxil fumarate combination therapy against a tenofovir-resistant simian/human immunodeficiency virus containing the K65R mutation in macaques.

Cong ME, Mitchell J, Sweeney E, Bachman S, Hanson DL, Heneine W, García-Lerma JG.

J Infect Dis. 2013 Aug 1;208(3):463-7. doi: 10.1093/infdis/jit189. Epub 2013 Apr 30.

2.

Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir.

García-Lerma JG, Otten RA, Qari SH, Jackson E, Cong ME, Masciotra S, Luo W, Kim C, Adams DR, Monsour M, Lipscomb J, Johnson JA, Delinsky D, Schinazi RF, Janssen R, Folks TM, Heneine W.

PLoS Med. 2008 Feb;5(2):e28. doi: 10.1371/journal.pmed.0050028.

3.

Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada.

Cong ME, Youngpairoj AS, Zheng Q, Aung W, Mitchell J, Sweeney E, Hanson DL, Hendry RM, Dobard C, Heneine W, García-Lerma JG.

J Virol. 2011 Aug;85(15):7933-6. doi: 10.1128/JVI.00843-11. Epub 2011 Jun 1.

4.

A polyvalent Clade B virus-like particle HIV vaccine combined with partially protective oral preexposure prophylaxis prevents simian-human immunodeficiency virus Infection in macaques and primes for virus-amplified immunity.

Ross TM, Pereira LE, Luckay A, McNicholl JM, García-Lerma JG, Heneine W, Eugene HS, Pierce-Paul BR, Zhang J, Hendry RM, Smith JM.

AIDS Res Hum Retroviruses. 2014 Nov;30(11):1072-81. doi: 10.1089/AID.2014.0030. Epub 2014 Jul 29.

5.

Repeated Vaginal SHIV Challenges in Macaques Receiving Oral or Topical Preexposure Prophylaxis Induce Virus-Specific T-Cell Responses.

Tsegaye TS, Butler K, Luo W, Radzio J, Srinivasan P, Sharma S, Aubert RD, Hanson DL, Dobard C, Garcia-Lerma JG, Heneine W, McNicholl JM, Kersh EN.

J Acquir Immune Defic Syndr. 2015 Aug 1;69(4):385-94. doi: 10.1097/QAI.0000000000000642.

6.

Short communication: no evidence of occult SHIV infection as demonstrated by CD8+ cell depletion after chemoprophylaxis-induced protection from mucosal infection in rhesus macaques.

Kersh EN, Luo W, Adams DR, Mitchell J, Garcia-Lerma JG, Heneine W, Folks TM, Butera S, Otten RA.

AIDS Res Hum Retroviruses. 2008 Apr;24(4):543-6. doi: 10.1089/aid.2007.0222.

PMID:
18370590
7.

Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges.

Subbarao S, Otten RA, Ramos A, Kim C, Jackson E, Monsour M, Adams DR, Bashirian S, Johnson J, Soriano V, Rendon A, Hudgens MG, Butera S, Janssen R, Paxton L, Greenberg AE, Folks TM.

J Infect Dis. 2006 Oct 1;194(7):904-11. Epub 2006 Aug 29.

8.

Delayed maturation of antibody avidity but not seroconversion in rhesus macaques infected with simian HIV during oral pre-exposure prophylaxis.

Curtis KA, Kennedy MS, Luckay A, Cong ME, Youngpairoj AS, Zheng Q, Smith J, Hanson D, Heneine W, Owen SM, García-Lerma JG.

J Acquir Immune Defic Syndr. 2011 Aug 15;57(5):355-62. doi: 10.1097/QAI.0b013e3182234a51.

PMID:
21637113
10.

Limited SHIV env diversification in macaques failing oral antiretroviral pre-exposure prophylaxis.

Zheng Q, Ruone S, Switzer WM, Heneine W, García-Lerma JG.

Retrovirology. 2012 May 9;9:40. doi: 10.1186/1742-4690-9-40.

11.

Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine.

Parikh UM, Dobard C, Sharma S, Cong ME, Jia H, Martin A, Pau CP, Hanson DL, Guenthner P, Smith J, Kersh E, Garcia-Lerma JG, Novembre FJ, Otten R, Folks T, Heneine W.

J Virol. 2009 Oct;83(20):10358-65. doi: 10.1128/JVI.01073-09. Epub 2009 Aug 5.

12.

HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.

Liegler T, Abdel-Mohsen M, Bentley LG, Atchison R, Schmidt T, Javier J, Mehrotra M, Eden C, Glidden DV, McMahan V, Anderson PL, Li P, Wong JK, Buchbinder S, Guanira JV, Grant RM; iPrEx Study Team.

J Infect Dis. 2014 Oct 15;210(8):1217-27. doi: 10.1093/infdis/jiu233. Epub 2014 Apr 16.

13.

Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.

García-Lerma JG, Aung W, Cong ME, Zheng Q, Youngpairoj AS, Mitchell J, Holder A, Martin A, Kuklenyik S, Luo W, Lin CY, Hanson DL, Kersh E, Pau CP, Ray AS, Rooney JF, Lee WA, Heneine W.

J Virol. 2011 Jul;85(13):6610-7. doi: 10.1128/JVI.00311-11. Epub 2011 Apr 27.

14.

Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen.

Radzio J, Aung W, Holder A, Martin A, Sweeney E, Mitchell J, Bachman S, Pau CP, Heneine W, García-Lerma JG.

PLoS One. 2012;7(12):e50632. doi: 10.1371/journal.pone.0050632. Epub 2012 Dec 4.

15.

Generation and mucosal transmissibility of emtricitabine- and tenofovir-resistant SHIV162P3 mutants in macaques.

Cong ME, Youngpairoj AS, Aung W, Sharma S, Mitchell J, Dobard C, Heneine W, Garcia-Lerma JG.

Virology. 2011 Apr 10;412(2):435-40. doi: 10.1016/j.virol.2011.01.038. Epub 2011 Feb 21.

16.

Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges.

Smith JM, Rastogi R, Teller RS, Srinivasan P, Mesquita PM, Nagaraja U, McNicholl JM, Hendry RM, Dinh CT, Martin A, Herold BC, Kiser PF.

Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16145-50. doi: 10.1073/pnas.1311355110. Epub 2013 Sep 16.

17.

Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.

Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, Chuck SL, Yale K, Liu HC, Warren DR, Ramanathan S, Kearney BP.

AIDS. 2011 Mar 27;25(6):F7-12. doi: 10.1097/QAD.0b013e328345766f.

PMID:
21412057
18.

Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.

Lehman DA, Baeten JM, McCoy CO, Weis JF, Peterson D, Mbara G, Donnell D, Thomas KK, Hendrix CW, Marzinke MA, Frenkel L, Ndase P, Mugo NR, Celum C, Overbaugh J, Matsen FA; Partners PrEP Study Team.

J Infect Dis. 2015 Apr 15;211(8):1211-8. doi: 10.1093/infdis/jiu677. Epub 2015 Jan 13.

19.

Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.

Flynn PM, Mirochnick M, Shapiro DE, Bardeguez A, Rodman J, Robbins B, Huang S, Fiscus SA, Van Rompay KK, Rooney JF, Kearney B, Mofenson LM, Watts DH, Jean-Philippe P, Heckman B, Thorpe E Jr, Cotter A, Purswani M; PACTG 394 Study Team.

Antimicrob Agents Chemother. 2011 Dec;55(12):5914-22. doi: 10.1128/AAC.00544-11. Epub 2011 Sep 6.

20.

Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection.

García-Lerma JG, Cong ME, Mitchell J, Youngpairoj AS, Zheng Q, Masciotra S, Martin A, Kuklenyik Z, Holder A, Lipscomb J, Pau CP, Barr JR, Hanson DL, Otten R, Paxton L, Folks TM, Heneine W.

Sci Transl Med. 2010 Jan 13;2(14):14ra4. doi: 10.1126/scitranslmed.3000391.

Items per page

Supplemental Content

Write to the Help Desk